Parsons Erin 4

What Happened

• Erin Parsons, a director of Kiora Pharmaceuticals, received a grant/award of a derivative option covering 25,000 shares on 2026-06-10. The reported acquisition price is $0.00, so no cash was exchanged in the Form 4 transaction. This was an equity award (not a market purchase or sale).

Key Details

• Transaction date: 2026-06-10; Form 4 filed 2026-06-12 (appears timely).
• Transaction code: A (award/grant of derivative securities).
• Shares/options granted: 25,000; reported acquisition price: $0.00 (derivative).
• Shares owned after transaction: not disclosed in this filing.
• Footnote: The option was granted under the Issuer’s 2024 Equity Incentive Plan and "will become fully exercisable on June 10, 2027" (vesting/exercisability condition noted).

Context

• This is a grant of an option (a derivative award). It does not indicate an immediate purchase of stock or exercise — the option becomes exercisable in one year. Grants are common for compensation and retention; they represent potential future ownership only if/when exercised according to the plan terms.